Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

GOSS

Gossamer Bio Inc

Feb 10 • 04:00PM ET

2.33

+0.07 3.10 %

Healthcare • Biotechnology • USA • NASD

Peers: BLUE CRSP SRPT FATE NTLA ADAP EDIT QURE BMRN VYGR

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA VHT VFMO

Index	RUT	P/E	-	EPS (ttm)	-0.69	Insider Own	20.13%	Shs Outstand	231.31M	Perf Week	-12.73%
Market Cap	539.29M	Forward P/E	-	EPS next Y	-0.58	Insider Trans	0.06%	Shs Float	184.86M	Perf Month	-6.80%
Enterprise Value	561.95M	PEG	-	EPS next Q	-0.19	Inst Own	62.18%	Short Float	14.49%	Perf Quarter	-1.27%
Income	-156.16M	P/S	12.24	EPS this Y	-187.92%	Inst Trans	0.50%	Short Ratio	6.02	Perf Half Y	34.29%
Sales	44.05M	P/B	-	EPS next Y	19.96%	ROA	-55.80%	Short Interest	26.78M	Perf YTD	-24.84%
Book/sh	-0.36	P/C	2.99	EPS next 5Y	1.52%	ROE	-783.37%	52W High	3.87 -39.79%	Perf Year	99.15%
Cash/sh	0.78	P/FCF	-	EPS past 3/5Y	56.92% 40.29%	ROIC	-130.54%	52W Low	0.76 206.58%	Perf 3Y	1.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	95.80%	Volatility	9.70% 9.16%	Perf 5Y	-78.00%
Dividend TTM	-	EV/Sales	12.76	EPS Y/Y TTM	-116.24%	Oper. Margin	-348.10%	ATR (14)	0.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.28	Sales Y/Y TTM	-58.17%	Profit Margin	-354.50%	RSI (14)	40.90	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	3.28	EPS Q/Q	-55.40%	SMA20	-7.79%	Beta	1.94	Target Price	9.43
Payout	-	Debt/Eq	-	Sales Q/Q	40.23%	SMA50	-20.59%	Rel Volume	1.48	Prev Close	2.26
Employees	145	LT Debt/Eq	-	Earnings	Nov 05 AMC	SMA200	4.65%	Avg Volume	4.45M	Price	2.33
IPO	Feb 08, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.78% 108.35%	Trades		Volume	6,552,975	Change	3.10%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$9
Sep-10-25	Upgrade	UBS	Neutral → Buy	$9
Jul-14-25	Initiated	Scotiabank	Sector Outperform	$11
Jun-25-24	Initiated	Oppenheimer	Outperform	$9
Apr-05-24	Resumed	Wedbush	Outperform	$4
Jul-27-23	Downgrade	UBS	Buy → Neutral	$8 → $1.25
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral	$3
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight	$18 → $2
Oct-20-22	Initiated	Goldman	Buy	$22
Sep-21-22	Initiated	JP Morgan	Neutral	$17
Sep-19-22	Initiated	Wedbush	Outperform	$24
Apr-18-22	Initiated	Raymond James	Outperform	$19
Apr-06-22	Initiated	UBS	Buy	$19
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform	$24
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight	$20
Sep-21-21	Resumed	Piper Sandler	Overweight	$26
Jun-29-20	Initiated	H.C. Wainwright	Buy	$31

Show Previous Ratings

Feb-06-26 11:02AM	Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation (Insider Monkey) -7.19%
Jan-08-26 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-21-25 07:31AM	Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data (Insider Monkey)
Dec-15-25 11:11PM	Oppenheimer Confident in Positive PROSERA Trial Readout in February 2026 for Gossamer Bio (GOSS) (Insider Monkey) +5.28% -6.07%
Dec-11-25 06:41PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
05:30PM	Loading…
Dec-09-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-24-25 04:01PM	Gossamer Bio to Participate in Upcoming Investor Conferences (Business Wire)
Nov-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.08%
07:31AM	Gossamer Bio to Participate in Upcoming Investor Conferences (Business Wire)
Nov-05-25 05:35PM	Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:29PM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Sep-25-25 07:41AM	Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital (PR Newswire) -7.02%
07:31AM	Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On-Demand Vardenafil for Pulmonary Hypertension (Business Wire)
Sep-23-25 07:22PM	Gossamer Bio, Inc. (GOSS) Stock Jumps 18% on FDA Updates and Seralutinib Progress (Insider Monkey)
07:31AM	Loading…
Sep-22-25 07:31AM	Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 (Business Wire)
Sep-11-25 01:15PM	H.C. Wainwright Asserts Buy Stance on Gossamer Bio Inc. (GOSS) on Pulmonary Arterial Hypertension Drug Prospects (Insider Monkey) +11.25%
03:31AM	Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case (Insider Monkey)
Sep-10-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.27%
Aug-29-25 07:31AM	Gossamer Bio to Present at Upcoming Investor Conferences (Business Wire)
Aug-19-25 12:06AM	H.C. Wainwright and Leerink Partners Reiterate 'Buy' Ratings on Gossamer Bio, Inc. (GOSS) (Insider Monkey)
Aug-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.12%
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -8.33%
04:53PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 07:05AM	GSK (GSK) Q2 Earnings and Revenues Beat Estimates (Zacks) +6.12%
Jun-24-25 12:46PM	Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib (Insider Monkey)
Jun-16-25 07:31AM	Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH (Business Wire)
Jun-06-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.56%
07:00AM	Loading…
May-21-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream (GlobeNewswire)
May-16-25 09:11AM	Q1 2025 Gossamer Bio Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ... (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:09PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study (Business Wire)
May-14-25 09:45AM	What To Expect From Gossamer Bio Inc (GOSS) Q1 2025 Earnings (GuruFocus.com) -7.34%
May-12-25 04:01PM	Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 (Business Wire)
May-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:01PM	Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference (Business Wire)
May-02-25 01:21PM	Gossamer Bio: Initiating Hold As Late-Stage Data Nears Inflection (Seeking Alpha) +11.32%
Apr-16-25 09:57AM	Is Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1? (Insider Monkey)
Apr-09-25 09:44AM	Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple (Insider Monkey) +11.76%
Apr-08-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-27-25 09:45AM	Is Gossamer Bio Inc. (GOSS) the Popular Penny Stock on Robinhood to Watch? (InsiderMonkey)
Mar-26-25 01:38PM	Is Gossamer Bio, Inc. (GOSS) The Hot Biotech Stock Under $5? (InsiderMonkey) -7.81%
Mar-23-25 08:41AM	Gossamer Bio (GOSS): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-13-25 05:10PM	Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +11.54%
04:06PM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.38%
Feb-03-25 07:01AM	Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress (Business Wire)
Jan-28-25 07:01AM	Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress (Business Wire)
Jan-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.41%
09:19AM	Why Gossamer Bio, Inc. (GOSS) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-26-24 12:00PM	Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-21-24 12:00PM	All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy (Zacks)
Nov-15-24 09:35AM	After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) (Zacks)
Nov-14-24 09:35AM	After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) (Zacks) -5.59%
Nov-11-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-24 06:00PM	Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:59PM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
04:03PM	Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Oct-31-24 07:00AM	NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule (GlobeNewswire)
Oct-30-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now (GlobeNewswire)
Oct-29-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now (GlobeNewswire)
Oct-07-24 05:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire)
Aug-26-24 04:01PM	Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024 (Business Wire)
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-12-24 10:53PM	GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:10PM	Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates (Zacks)
04:15PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 02:35AM	Why Is Gossamer Bio, Inc. (GOSS) the Best One-Dollar Stock to Buy Now? (Insider Monkey)
Jun-13-24 03:35PM	The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street (InvestorPlace)
Jun-07-24 04:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.60% -6.09%
May-14-24 04:01PM	Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference (Business Wire)
May-10-24 04:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-07-24 10:56PM	GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024 (InvestorPlace) -6.30%
05:15PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
05:11AM	Gossamer Bio and Chiesi partner for pulmonary hypertension treatment (Pharmaceutical Technology)
04:31AM	Gossamer Bio and Chiesi link for pulmonary hypertension treatment (Pharmaceutical Technology)
May-06-24 03:17PM	Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide (Benzinga) +5.50%
08:17AM	UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition (Reuters)
08:11AM	Gossamer sells rights to drug it hopes can rival a new Merck therapy (BioPharma Dive)
07:41AM	Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment (Reuters)
07:30AM	Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications (Business Wire)
May-03-24 08:02AM	Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine (Business Wire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 07:31AM	Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors (Business Wire)
Mar-07-24 09:55AM	Should You Buy Gossamer Bio (GOSS) After Golden Cross? (Zacks) -7.95%
Mar-05-24 10:52PM	GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023 (InvestorPlace)
07:55AM	Gossamer Bio Posts Narrower Loss In Q4 - Quick Facts (RTT News)
07:40AM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Milligan Sandra	Director	Aug 19 '25	Buy	1.92	26,050	50,016	58,050	Aug 20 04:04 PM

Open in Screener

PTGX

Protagonist Therapeutics Inc

Feb 10 • 04:00PM ET

83.88

+0.56 0.67 %

Healthcare • Biotechnology • USA • NASD

PTGX Protagonist Therapeutics Inc daily Stock Chart

Peers: AMGN REGN CRSP VRTX NTLA BLUE ARWR EDIT AKRO SGMO

| Held by: IJR VTI IWM XBI VB VXF SPSM IJT IWO IBB

Index	RUT	P/E	132.43	EPS (ttm)	0.63	Insider Own	5.63%	Shs Outstand	62.45M	Perf Week	-2.00%
Market Cap	5.24B	Forward P/E	57.61	EPS next Y	1.46	Insider Trans	-5.70%	Shs Float	58.99M	Perf Month	4.56%
Enterprise Value	4.68B	PEG	-	EPS next Q	-0.33	Inst Own	113.15%	Short Float	13.79%	Perf Quarter	5.46%
Income	45.91M	P/S	25.06	EPS this Y	-139.20%	Inst Trans	4.22%	Short Ratio	9.21	Perf Half Y	56.06%
Sales	209.22M	P/B	8.12	EPS next Y	187.81%	ROA	7.03%	Short Interest	8.13M	Perf YTD	-3.96%
Book/sh	10.34	P/C	9.10	EPS next 5Y	-	ROE	7.80%	52W High	96.54 -13.11%	Perf Year	120.79%
Cash/sh	9.22	P/FCF	82.31	EPS past 3/5Y	- -	ROIC	7.02%	52W Low	33.70 148.90%	Perf 3Y	387.39%
Dividend Est.	-	EV/EBITDA	227.99	Sales past 3/5Y	151.35% 351.71%	Gross Margin	99.28%	Volatility	4.25% 4.24%	Perf 5Y	241.11%
Dividend TTM	-	EV/Sales	22.36	EPS Y/Y TTM	-72.97%	Oper. Margin	9.09%	ATR (14)	3.41	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.05	Sales Y/Y TTM	-35.39%	Profit Margin	21.94%	RSI (14)	50.74	Recom	1.23
Dividend Gr. 3/5Y	- -	Current Ratio	13.05	EPS Q/Q	-14.73%	SMA20	0.97%	Beta	2.25	Target Price	101.08
Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	0.79%	SMA50	-2.08%	Rel Volume	0.49	Prev Close	83.32
Employees	126	LT Debt/Eq	0.01	Earnings	Nov 06 AMC	SMA200	25.89%	Avg Volume	883.27K	Price	83.88
IPO	Aug 11, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.10% 31.51%	Trades		Volume	442,583	Change	0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-25	Initiated	Barclays	Overweight	$72
Sep-12-25	Initiated	Leerink Partners	Outperform	$73
Jun-17-25	Initiated	Citigroup	Buy	$72
Dec-06-24	Initiated	Goldman	Neutral	$47
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$62
Nov-05-24	Initiated	Wedbush	Outperform	$58
Sep-24-24	Initiated	TD Cowen	Buy	$65
Sep-09-24	Initiated	Truist	Buy	$60
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight	$53
Sep-18-20	Reiterated	H.C. Wainwright	Buy	$28 → $33

Show Previous Ratings

Jan-07-26 07:30AM	Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 (ACCESSWIRE)
Jan-06-26 04:29PM	Alumis Stock Catapults More Than 95% As Biotech Takes On J&J, Protagonist In Psoriasis (Investor's Business Daily)
07:05AM	Takeda and Protagonist seek FDA approval for rusfertide to treat PV (Pharmaceutical Technology)
Jan-05-26 07:00AM	Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) (Business Wire)
Dec-06-25 09:30AM	Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera (Business Wire)
04:21PM	Loading…
Dec-05-25 04:21PM	Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory (Insider Monkey)
Nov-27-25 03:45AM	Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice (ACCESSWIRE)
Nov-06-25 05:45PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:42PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-04-25 10:00AM	Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-03-25 04:05PM	Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting (ACCESSWIRE)
Oct-30-25 10:00AM	Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 07:40AM	Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
07:35AM	Loading…
Oct-27-25 07:35AM	Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences (ACCESSWIRE)
Oct-18-25 12:04PM	Johnson & Johnson's M&A Strategy Is the Real Story for Investors (MarketBeat)
Oct-13-25 02:50PM	Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal (Zacks) -9.00%
06:46AM	J&J in talks to acquire Protagonist Therapeutics (Pharmaceutical Technology)
Oct-10-25 07:07PM	Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today (Motley Fool) +29.77%
02:21PM	Trump's China tariff threat sinks stocks, Applied Digital surges (Yahoo Finance Video)
01:38PM	RTW Investments' Rod Wong: Expect more deals in biotech space (CNBC TV)
11:53AM	Protagonist Therapeutics stock surges after J&J acquisition talks report (Investing.com)
11:23AM	Protagonist Stock Surges on Johnson & Johnson Report (The Wall Street Journal)
11:13AM	Johnson & Johnson in Talks to Buy Protagonist Therapeutics (The Wall Street Journal)
10:23AM	Stock Market Today: Market Tumbles After Trump Threatens "Massive Increase" on China Tariffs (TheStreet)
Oct-07-25 08:10AM	Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill (ACCESSWIRE)
Sep-17-25 11:45AM	Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory (Insider Monkey)
08:00AM	Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress (ACCESSWIRE)
Sep-15-25 10:45AM	Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 (ACCESSWIRE)
11:36AM	Loading…
Sep-12-25 11:36AM	JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
Sep-11-25 08:00AM	Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency (ACCESSWIRE)
Aug-26-25 04:05PM	Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 (ACCESSWIRE) +7.79%
Aug-25-25 07:00AM	Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera (ACCESSWIRE)
Aug-06-25 05:25PM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:24PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-22-25 11:51AM	JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
Jul-21-25 08:05AM	Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis (ACCESSWIRE)
Jun-30-25 04:09PM	Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? (Investor's Business Daily) -9.16%
04:05PM	Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity (ACCESSWIRE)
Jun-26-25 07:05AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate (ACCESSWIRE)
Jun-24-25 03:09PM	Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera (Insider Monkey)
Jun-23-25 01:17PM	Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains? (Zacks)
09:07AM	Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? (Zacks)
Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com)
Jun-09-25 10:00AM	For Patients With Rare Blood Cancer, New Drug Offers Relief (The Wall Street Journal)
Jun-01-25 08:00AM	Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera (Business Wire)
May-27-25 09:29AM	Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome (Insider Monkey)
May-21-25 07:05AM	Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 (ACCESSWIRE)
May-12-25 08:11AM	J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study (Zacks) +5.35%
May-09-25 10:27AM	Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
08:05AM	Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting (ACCESSWIRE)
May-06-25 06:30PM	Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.13%
04:05PM	Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-23-25 10:35AM	Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 (ACCESSWIRE)
Apr-10-25 08:10AM	Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill (ACCESSWIRE)
Apr-01-25 02:27PM	Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns (Seeking Alpha)
Mar-25-25 09:55AM	Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? (Zacks)
Mar-18-25 02:10PM	Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) Best Biotech Stock for 2025? (Insider Monkey)
07:00AM	These 10 biotech companies are changing how we discover new drugs and treat complex diseases (FastCompany)
07:00AM	Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 (ACCESSWIRE)
Mar-15-25 04:40PM	Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? (Insider Monkey)
Mar-12-25 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why (Zacks)
Mar-11-25 09:29AM	Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success (GuruFocus.com) +6.81%
08:37AM	J&J and Protagonists icotrokinra scores in Phase IIb UC study (Clinical Trials Arena)
06:47AM	Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday (Insider Monkey)
Mar-10-25 04:30PM	Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out (Investor's Business Daily) +45.89%
08:15AM	Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis (ACCESSWIRE)
Mar-08-25 09:15AM	Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis (ACCESSWIRE)
Mar-03-25 12:01PM	Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer (Benzinga)
10:25AM	Takeda and Protagonist report topline outcomes from trial of rusfertide (Clinical Trials Arena)
06:45AM	Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera (Business Wire)
06:29AM	Protagonist says Takeda-partnered drug succeeds in rare blood cancer (BioPharma Dive)
Feb-21-25 08:35AM	Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:34AM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-12-25 07:51AM	Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
Jan-29-25 06:15PM	Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025 (ACCESSWIRE)
Jan-06-25 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Dec-19-24 04:05PM	Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 (ACCESSWIRE)
Dec-09-24 04:05PM	Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting (ACCESSWIRE)
Dec-06-24 06:48AM	Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities (TipRanks)
Nov-22-24 07:30AM	Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 (ACCESSWIRE) +11.55%
Nov-21-24 04:05PM	Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-19-24 07:30AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-18-24 04:30PM	Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor (ACCESSWIRE)
Nov-13-24 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-07-24 05:30PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:56PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-05-24 04:05PM	Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting (ACCESSWIRE)
Oct-29-24 09:27AM	Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million (ACCESSWIRE)
Oct-18-24 06:28AM	Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases (Insider Monkey)
Oct-16-24 03:03PM	State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc (GuruFocus.com)
Sep-10-24 01:17PM	Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines (Benzinga)
Sep-03-24 07:30AM	Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 (ACCESSWIRE)
Aug-06-24 01:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
08:20AM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Waddill William D.	Director	Feb 06 '26	Option Exercise	8.31	20,000	166,200	27,825	Feb 06 04:38 PM
Waddill William D.	Director	Feb 06 '26	Sale	83.68	20,000	1,673,600	7,825	Feb 06 04:38 PM
WILLIAM D WADDILL	Director	Feb 06 '26	Proposed Sale	83.68	20,000	1,673,672		Feb 06 04:04 PM
PATEL DINESH V PH D	President and CEO	Jan 26 '26	Option Exercise	14.12	24,890	351,528	588,710	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 27 '26	Option Exercise	21.58	4,068	87,787	578,573	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 23 '26	Option Exercise	4.21	19,315	81,316	593,820	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 26 '26	Sale	84.03	24,890	2,091,470	574,505	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 23 '26	Sale	84.59	19,315	1,633,856	574,505	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 27 '26	Sale	83.19	4,068	338,417	574,505	Jan 27 09:21 PM
Ali Asif	Chief Financial Officer	Jan 27 '26	Option Exercise	16.18	28,000	453,080	106,523	Jan 27 09:20 PM
Ali Asif	Chief Financial Officer	Jan 27 '26	Sale	83.13	46,203	3,841,037	60,320	Jan 27 09:20 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 27 '26	Option Exercise	8.04	5,000	40,200	89,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 26 '26	Option Exercise	8.04	5,000	40,200	89,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 23 '26	Sale	82.42	13,151	1,083,905	84,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 26 '26	Sale	82.28	5,000	411,400	84,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 27 '26	Sale	82.00	5,000	410,000	84,115	Jan 27 09:19 PM
ASIF ALI	Officer	Jan 27 '26	Proposed Sale	83.14	46,203	3,841,128		Jan 27 05:12 PM
ARTURO MOLINA	Officer	Jan 27 '26	Proposed Sale	82.00	5,000	410,000		Jan 27 04:01 PM
ARTURO MOLINA	Officer	Jan 26 '26	Proposed Sale	82.28	5,000	411,396		Jan 26 04:29 PM
ARTURO MOLINA	Officer	Jan 23 '26	Proposed Sale	83.42	13,151	1,097,116		Jan 23 04:32 PM
Dinesh Patel	CEO	Jan 23 '26	Proposed Sale	84.62	108,273	9,162,061		Jan 23 04:06 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 20 '26	Sale	82.48	9,514	784,715	97,266	Jan 21 05:17 PM
PATEL DINESH V PH D	President and CEO	Jan 20 '26	Sale	82.48	34,438	2,840,446	580,505	Jan 21 05:16 PM
Ali Asif	Chief Financial Officer	Jan 20 '26	Sale	82.48	8,588	708,338	78,077	Jan 21 05:15 PM
ARTURO MOLINA MD	Officer	Jan 20 '26	Proposed Sale	82.48	9,514	784,715		Jan 21 05:12 PM
DINESH V PATEL PH D	Officer, Director	Jan 20 '26	Proposed Sale	82.48	34,438	2,840,446		Jan 21 05:11 PM
Asif Ali	Officer	Jan 20 '26	Proposed Sale	82.48	8,588	708,338		Jan 21 05:10 PM
SELICK HAROLD E	Director	Jan 09 '26	Option Exercise	4.21	14,299	60,199	60,845	Jan 13 04:45 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 17 '25	Sale	84.77	2,712	229,896	81,180	Nov 19 04:01 PM
Waddill William D.	Director	Oct 10 '25	Option Exercise	6.98	12,000	83,760	17,130	Oct 14 04:01 PM
Waddill William D.	Director	Oct 10 '25	Sale	81.62	12,000	979,480	5,130	Oct 14 04:01 PM
WILLIAM WADDILL	Director	Oct 10 '25	Proposed Sale	67.04	12,000	804,480		Oct 10 04:18 PM
Waddill William D.	Director	Sep 22 '25	Sale	64.25	4,000	257,000	5,130	Sep 24 08:35 PM
WILLIAM WADDILL	Director	Sep 22 '25	Proposed Sale	62.20	4,000	248,800		Sep 22 04:27 PM
Waddill William D.	Director	Aug 27 '25	Sale	59.25	4,000	237,000	9,130	Aug 29 05:30 PM
WILLIAM WADDILL	Director	Aug 27 '25	Proposed Sale	56.99	4,000	227,960		Aug 27 04:33 PM
PATEL DINESH V PH D	President and CEO	Jul 25 '25	Sale	54.78	10,415	570,534	520,603	Jul 28 06:08 PM
PATEL DINESH V PH D	President and CEO	Jul 22 '25	Sale	55.05	22,065	1,214,678	548,538	Jul 23 06:57 PM
PATEL DINESH V PH D	President and CEO	Jul 23 '25	Sale	54.79	17,520	959,921	531,018	Jul 23 06:57 PM
PATEL DINESH V PH D	President and CEO	Jul 21 '25	Sale	54.86	12,859	705,445	570,603	Jul 23 06:57 PM
Dinesh Patel	CEO	Jul 22 '25	Proposed Sale	55.22	50,000	2,761,000		Jul 22 04:04 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 09 '25	Option Exercise	8.04	10,000	80,400	93,892	Jun 11 05:40 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 10 '25	Option Exercise	8.04	10,000	80,400	93,892	Jun 11 05:40 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 10 '25	Sale	57.03	10,000	570,300	83,892	Jun 11 05:40 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 09 '25	Sale	55.51	10,000	555,100	83,892	Jun 11 05:40 PM
ARTURO MOLINA	Officer	Jun 10 '25	Proposed Sale	57.03	10,000	570,269		Jun 10 05:51 PM
ARTURO MOLINA	Officer	Jun 09 '25	Proposed Sale	55.51	10,000	555,077		Jun 09 04:46 PM
SELICK HAROLD E	Director	Apr 28 '25	Option Exercise	1.16	10,725	12,441	43,851	Apr 30 04:45 PM
Ali Asif	Chief Financial Officer	Apr 22 '25	Sale	46.00	1,756	80,776	61,065	Apr 23 04:30 PM
Waddill William D.	Director	Mar 17 '25	Sale	54.25	4,000	217,000	13,130	Mar 19 04:01 PM
WILLIAM D WADDILL	Director	Mar 17 '25	Proposed Sale	54.78	4,000	219,120		Mar 17 04:30 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 13 '25	Option Exercise	24.48	30,514	746,956	114,406	Mar 14 06:21 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 13 '25	Sale	55.74	30,514	1,700,850	83,892	Mar 14 06:21 PM
Ali Asif	Chief Financial Officer	Mar 12 '25	Option Exercise	14.90	24,903	371,164	87,724	Mar 14 06:20 PM
Ali Asif	Chief Financial Officer	Mar 12 '25	Sale	58.73	24,903	1,462,553	62,821	Mar 14 06:20 PM
MOLINA ARTURO MD	Officer	Mar 13 '25	Proposed Sale	55.00	30,514	1,678,270		Mar 13 05:24 PM
Ali Asif	Officer	Mar 12 '25	Proposed Sale	58.73	24,903	1,462,587		Mar 12 05:31 PM
PATEL DINESH V PH D	President and CEO	Mar 05 '25	Option Exercise	4.21	24,000	101,040	564,260	Mar 05 08:02 PM
PATEL DINESH V PH D	President and CEO	Feb 19 '25	Sale	38.18	5,359	204,607	540,260	Feb 20 05:25 PM

GOSS

Gossamer Bio Inc

PTGX

Protagonist Therapeutics Inc

Upgrade your FINVIZ experience